Fig. 5

Flow-cytometry analysis of glycolysis in the cGAMP-injected B16F10 model. a Percentage of GLUT1 (left) and HX2 (right) high expressing cells in CD45⁻ cancer cells (top) or CD45⁺ immune cells (bottom) in tumors on day 7 (n = 5–7). Data of the non-treatment group and anti-PD-1-treated group were quoted from [11]. b Percentage of GLUT1 (left) and HX2 (right) high expressing cells in CD45⁺ immune cells in spleens on day 7 (n = 5–7). Data of the non-treatment group and anti-PD-1-treated group were quoted from [11]. Data represent the mean ± SEM; *p < 0.05; **p < 0.01; † Adapted from [11]